Project Grant R01HL174785
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$692K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $734,463 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Methodist Hospital Research Institute Division to advance the treatment of peripheral artery disease (PAD). The key products and services to be delivered under this 5-year award include:
Establishing a novel MRI-histology anatomic scoring system to predict immediate technical failure of percutaneous vascular interventions (PVI) and...
This $761,042 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the mechanisms driving medial arterial calcification (MAC) in peripheral artery disease (PAD). The University of Pittsburgh, the primary awardee, will conduct complementary studies to: 1) define how the DNA damage response promotes vascular calcification, and 2) determine how reduced adenosine production...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $736,752 to develop and test a novel Axially Prestretched Elastomeric Nanofibrillar Graft (APENG) for lower extremity arterial reconstructions. The project aims to address the high failure rates of existing synthetic vascular grafts used in treating lower extremity arterial disease. The APENG concept incorporates axial prestretch to...
This federal Project Grant award, valued at $153,252 and granted by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a 3-year research program to investigate the role of a specific macrophage population (SPP1+ macrophages) in skeletal muscle regeneration in peripheral arterial disease (PAD).
The key objectives are to determine if SPP1+ macrophages inhibit muscle stem cell regeneration and macrophage polarization...
This $656,751 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) funds the development of an artificial intelligence (AI)-based platform called TCDFLOW by Third Coast Dynamics, Inc. The platform aims to provide 4D hemodynamic assessment of thoracic aortic aneurysms directly from routine clinical anatomic images, without the need for specialized 4D flow MRI techniques and expertise. The two-phase...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $340,956 to Agex Therapeutics Inc. to develop novel, highly regenerative, and scalable progenitor cell exosomes for treating peripheral artery disease (PAD).
The goal of this Phase I Small Business Innovation Research (STTR) project is to demonstrate the therapeutic feasibility of using exosomes derived from Agex's proprietary PureStem...
This $510,772 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) supports research and development to advance an innovative ultrasound-based technology to induce neovascularization and enhance local tissue perfusion. The key objectives are to: 1) develop systematic protocols to fabricate functional microvessel networks within patterned hydrogels, 2)...
This $295,922 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and demonstrate a novel "PERISCOPE" device that enables fluoroscopy-free pericardial access for epicardial ablation procedures. The project aims to 1) reduce the access needle size while maintaining high-quality color imaging, and 2) develop a color imaging introducer to visualize ablation catheters entering the...
This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is providing $2,529,292 to Northwestern University to conduct the IMPACT PAD clinical trial. The trial aims to evaluate the impact of home-based exercise and nitrate-rich beetroot juice supplementation on improving walking performance in patients undergoing lower extremity revascularization procedures for peripheral artery disease...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a "4D Right-Heart Virtual Catheter (VCATH)" to provide a comprehensive, non-invasive assessment of hemodynamics in pulmonary hypertension patients. The $691,326 award to Northwestern University, with sub-awards to Mayo Clinic and UT Southwestern Medical Center, will fund the creation of an automated 4D-flow MRI-based solution to diagnose...